AXGN
NASDAQAxogen Inc.
SectorHealth CareIndustryBiotechnology: Electromedical & Electrotherapeutic Apparatus
News · 26 weeks47-33%
2026-03-012026-08-23
Mix2590d
- Insider17(68%)
- SEC Filings3(12%)
- Earnings2(8%)
- Leadership2(8%)
- Other1(4%)
Latest news
25 items- INSIDEREVP & General Counsel Began Marc A exercised 67,500 shares at a strike of $8.16 and sold $3,195,788 worth of shares (67,500 units at $47.34) as part of a pre-agreed trading plan (SEC Form 4)4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERDirector Wendell Amy Mcbride exercised 13,353 shares at a strike of $14.85 and sold $646,592 worth of shares (13,353 units at $48.42) as part of a pre-agreed trading plan (SEC Form 4)4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERDirector Weiler Kathy Johnson sold $640,967 worth of shares (14,150 units at $45.30) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)4 - Axogen, Inc. (0000805928) (Issuer)
- PRCosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill ItRENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and partly because the science moved. When dermatologists, facial plastic surgeons and aesthetic medicine specialists gather this week at the Controversies & Conversation
- SECSEC Form 10-Q filed by Axogen Inc.10-Q - Axogen, Inc. (0000805928) (Filer)
- SECAxogen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Axogen, Inc. (0000805928) (Filer)
- PRTrace Biosciences Announces Strategic Investment from Axogen to Advance Clinical Development of its Nerve Trace Nerve-Specific Imaging TechnologyPORTLAND, Ore., July 29, 2026 /PRNewswire/ -- Trace Biosciences, Inc., a clinical-stage biotechnology company developing nerve-targeted imaging agents, today announced it has received a strategic investment from Axogen, Inc. (NASDAQ:AXGN), the global leader in surgical solutions for restoration of peripheral nerve function, as its technology continues to advance through clinical development. The investment is part of Trace's Series A financing round with additional investors expected to join. Nerve Trace is a near-infrared fluorescence imaging technology designed to provide direct, real-time visualization of nerves during surge
- PRAxogen, Inc. Reports Second Quarter 2026 Financial ResultsALACHUA, Fla. and TAMPA, Fla., July 29, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the second quarter ended June 30, 2026. Second Quarter Financial Results Revenue was $69.7 million, an increase of 23.1% compared with $56.7 million in the second quarter of 2025.Gross margin was 72.7% compared to 74.2% in the second quarter of 2025. Gross margin performance was driven by changes in product mix caused primarily by accelerating year over year Breast growth greater than 50%.Net loss was $1.5
- PRNeuronetics Appoints Nir Naor Chief Financial Officer; Announces Additional Management ChangesNir Naor appointed Chief Financial Officer effective July 23, 2026, bringing more than 20 years of finance and life sciences experienceCory Anderson promoted to Executive Vice President and General Manager, Greenbrook effective July 1, 2026Andrew Macan to step down as Executive Vice President, Chief Legal Officer & Corporate Secretary, effective August 15, 2026 MALVERN, Pa., July 20, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced that Nir Naor will be appointed Chief Financial Officer e
- PRAxogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026ALACHUA, Fla. and TAMPA, Fla., July 15, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the second quarter of 2026 on Wednesday, July 29, 2026. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release. Investors interested in participating in the conference call by phone may dial toll-free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. A live webcast, an archived replay, and presentation slides from the event are availabl
- INSIDERSEC Form 4 filed by Director Burke William P. Mr.4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERSEC Form 4 filed by Director Tyndall Joseph A.4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERSEC Form 4 filed by Director Levine Alan M4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERSEC Form 4 filed by Director Johnson John4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERSEC Form 4 filed by Director Thomas Paul4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERSEC Form 4 filed by Director Wendell Amy Mcbride4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERSEC Form 4 filed by Director Weiler Kathy Johnson4 - Axogen, Inc. (0000805928) (Issuer)
- SECAxogen Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Axogen, Inc. (0000805928) (Filer)
- INSIDERDirector Levine Alan M converted options into 14,150 shares, increasing direct ownership by 39% to 50,893 units (SEC Form 4)4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERDirector Weiler Kathy Johnson converted options into 14,150 shares (SEC Form 4)4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERDirector Wendell Amy Mcbride converted options into 14,150 shares, increasing direct ownership by 15% to 107,976 units (SEC Form 4)4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERDirector Thomas Paul converted options into 18,867 shares, increasing direct ownership by 139% to 32,395 units (SEC Form 4)4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERDirector Tyndall Joseph A. converted options into 14,150 shares (SEC Form 4)4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERDirector Johnson John converted options into 14,150 shares (SEC Form 4)4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERDirector Burke William P. Mr. converted options into 14,150 shares, increasing direct ownership by 14,150% to 14,250 units (SEC Form 4)4 - Axogen, Inc. (0000805928) (Issuer)
AXGN FAQ
6 questionsWhat does Axogen Inc. do?
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged...Where does AXGN stock trade?
Axogen Inc. (AXGN) is listed on NASDAQ.What sector and industry is AXGN in?
Axogen Inc. operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.What are analysts saying about AXGN?
Axogen Inc. has had 8 recent analyst actions on file. The most recent action was from Wells Fargo: Overweight with a $4000.00 price target on 2026-02-19. Recent price targets range from $1300.00 to $4000.00.What companies are similar to AXGN?
Notable peers in the same industry include MDT (Medtronic plc.), MASI (Masimo Corporation), SEAS (SeaWorld Entertainment Inc.), LIVN (LivaNova PLC), ITGR (Integer Holdings Corporation). Compare AXGN side-by-side with any of them on Quantisnow.How can I track AXGN on Quantisnow?
Quantisnow aggregates Axogen Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AXGN to receive live email and push alerts on every new disclosure.